Astellas Pharma Inc. Patent applications |
Patent application number | Title | Published |
20160137985 | METHOD FOR PRODUCING RENAL PROGENITOR CELLS, AND DRUG COMPRISING THE SAME - The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGFβ signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells. | 05-19-2016 |
20160113917 | MEDICINAL COMPOSITION FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR SHRINKING SAME - Provided is a pharmaceutical composition which enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm. The pharmaceutical composition for the inhibition of formation and/or enlargement of cerebral aneurysm or for the regression of cerebral aneurysm of the present invention, which includes a S1P | 04-28-2016 |
20160046720 | NOVEL ANTI-HUMAN TSLP RECEPTOR ANTIBODY - [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. | 02-18-2016 |
20160045479 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance. | 02-18-2016 |
20160031847 | GUANIDINOBENZOIC ACID ESTER COMPOUND - [Problem]To provide a compound which is useful as an agent for preventing and/or treating kidney diseases. | 02-04-2016 |
20160002218 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | 01-07-2016 |
20150315208 | BENZAZEPINE COMPOUND - Provided is a compound which is useful as an agent for treating or preventing 5-HT | 11-05-2015 |
20150266869 | BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND | 09-24-2015 |
20150259299 | METHOD FOR PRODUCING SULFONYL AMIDINE COMPOUND - Provided are a method for producing a sulfonyl amidine compound, which has an excellent gonadotropin releasing hormone receptor antagonism and is useful as a therapeutic agent for gonadotropin-dependent diseases (for example, prostate cancer, breast cancer, endometriosis, uterine fibroid, prostatic hyperplasia, or the like) or a salt thereof, and a synthesis intermediate useful in the production method. The production method of the present invention controls formation of a by-product which is hardly removed unless column purification is conducted and racemization of a target compound, thereby obtaining the target compound with a high purity, and therefore, the production method is suitable for industrial production. | 09-17-2015 |
20150232464 | IMIDAZOPYRIDINE COMPOUNDS | 08-20-2015 |
20150231138 | SULFUR-CONTAINING BICYCLIC COMPOUND - A sulfur-containing bicyclic compound of the present invention has a PAM action of GABA | 08-20-2015 |
20150225453 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 08-13-2015 |
20150218265 | NOVEL ANTI-HUMAN NGF ANTIBODY - To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. An anti-human NGF antibody Fab′ fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4. | 08-06-2015 |
20150203505 | INDOLE CARBOXAMIDE DERIVATIVE | 07-23-2015 |
20150203480 | GUANIDINE COMPOUND | 07-23-2015 |
20150184161 | EML4-ALK FUSION GENE - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene | 07-02-2015 |
20150141641 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD - The present invention provides a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound which has an superior agonistic activity to an arginine vasopressin V2 receptor and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, or the like; and useful intermediates for use in the methods. The production method of the present invention is suitable for the industrial production of a medicament, because of a smaller number of steps, a higher yield, and a lower cost, as compared with the methods in the related art. | 05-21-2015 |
20150133433 | BENZOTHIOPHENE COMPOUND - A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: | 05-14-2015 |
20150126713 | Novel Anti-Human IL-23 Receptor Antibody - [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. | 05-07-2015 |
20150126488 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND - [Problem] On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. | 05-07-2015 |
20150111876 | SULFUR-CONTAINING BICYCLIC COMPOUND - A sulfur-containing bicyclic compound having a PAM action of GABA | 04-23-2015 |
20150045402 | HETEROCYCLIC ACETAMIDE COMPOUND - A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like. | 02-12-2015 |
20150031727 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE - [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. | 01-29-2015 |
20150031703 | NOVEL FGFR3 FUSION - [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. | 01-29-2015 |
20140378459 | GUANIDINOBENZOIC ACID COMPOUND | 12-25-2014 |
20140371196 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND - Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer. | 12-18-2014 |
20140364421 | BENZOTHIOPHENE COMPOUND - [Problem] A compound which is useful as an IK1 channel activator is provided. | 12-11-2014 |
20140343258 | NOVEL ANTI-HUMAN CTGF ANTIBODY - [Problem] An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. | 11-20-2014 |
20140329802 | TETRAHYDROBENZOTHIOPHENE COMPOUND - The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. | 11-06-2014 |
20140323463 | PYRAZINECARBOXAMIDE COMPOUND | 10-30-2014 |
20140315963 | HETEROCYCLIC ACETAMIDE COMPOUND - [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. | 10-23-2014 |
20140275490 | Novel Anti-Human IL-23 Receptor Antibody - [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases in which human IL-23R is involved in pathogenesis. | 09-18-2014 |
20140275105 | CRYSTAL OF ANDROGEN RECEPTOR ANTAGONISTIC COMPOUND - [Problem] A crystal of (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide with excellent activity as an androgen receptor (AR) antagonistic compound, the salts thereof, or the solvate thereof, which is suitable for industrialization as a bulk drug of pharmaceutical products; a pharmaceutical composition comprising the crystal as an active ingredient; and the pharmaceutical composition which is the AR antagonistic drug are provided. | 09-18-2014 |
20140249151 | BICYCLIC HETEROCYCLIC COMPOUND - [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11β-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. | 09-04-2014 |
20140242158 | Granular Pharmaceutical Composition - The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function. | 08-28-2014 |
20140220035 | METHOD FOR DETECTING NOVEL FGFR4 MUTANT - [Problem] An object of the present invention is to elucidate a novel genetic mutation which is a cause of cancer, and thereby, to provide a method for detecting the genetic mutation, or a protein which has the mutation, a method for detecting the presence of cancer in a subject, a method for diagnosing cancer in a subject, and a primer set, a probe and a detecting kit for the methods. | 08-07-2014 |
20140179749 | FORMULATIONS OF ENZALUTAMIDE - This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders. | 06-26-2014 |
20140179695 | CHROMANE COMPOUNDS - The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β-amyloid precursor protein, and/or β-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease. | 06-26-2014 |
20140155582 | NOVEL ANTI-HUMAN NGF ANTIBODY - [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. | 06-05-2014 |
20140142084 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND - Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. | 05-22-2014 |
20140100256 | FORMULATIONS OF ENZALUTAMIDE - This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders. | 04-10-2014 |
20140100210 | GUANIDINE COMPOUND | 04-10-2014 |
20140088080 | IMIDAZOPYRIDINE COMPOUNDS | 03-27-2014 |
20140066385 | METHOD FOR TREATING CANCER BY COMBINED USE OF DRUGS - A composition and method for cancer treatment comprising FK330 or a salt thereof as an active ingredient, which is for combined administration with one or more anti-tumor agents selected from taxane-family anti-tumor agents, and according to an embodiment, a composition for treatment of prostatic cancer or ovarian cancer. This abstract is not limiting of the invention. | 03-06-2014 |
20130338358 | METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND AND SYNTHETIC INTERMEDIATE THEREFOR - Provided is a method for producing a di(arylamino)aryl compound that has superior inhibitory activity against the kinase activities of EML4-ALK fusion protein and mutant EGFR protein and is useful as an active ingredient in pharmaceutical compositions for cancer treatment. The production method includes no purification step using silica gel column chromatography or no step possibly producing a mutagenic mesylate ester as a by-product, greatly improves overall yield, and is high yield and low cost and suitable for the industrial production of pharmaceutical products. Also provided is a synthetic intermediate that is useful in the production method. | 12-19-2013 |
20130317010 | TETRAHYDROISOQUINOLINE DERIVATIVE - To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT | 11-28-2013 |
20130310373 | PYRIMIDINE COMPOUND | 11-21-2013 |
20130261986 | METHOD FOR DETERMINING LIPOPHILICITY - An object of the present invention is to provide a method for rapidly and accurately determining the lipophilicity of a wide variety of substances. The lipophilicity of a wide variety of substances can be accurately and rapidly determined by making lipophilicity determination using multiple solvent systems with varied ratios of hydrophobic and hydrophilic solvents | 10-03-2013 |
20130231320 | SUBSTITUTED AMIDE COMPOUND - A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: | 09-05-2013 |
20130225553 | PYRAZOLOQUINOLINE COMPOUND - The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, bladder/urethral diseases, and the like, and thus, have found that a pyrazoloquinoline compound has a PDE9-inhibiting action, thereby completing the present invention. | 08-29-2013 |
20130197009 | ANTAGONIST FOR MUTANT ANDROGEN RECEPTOR - [Problem] An object of the present invention is to provide a novel anticancer drug which is useful for treating prostate cancer accompanying androgen receptor mutation | 08-01-2013 |
20130165491 | THERAPEUTIC AGENT FOR PAIN | 06-27-2013 |
20130158095 | EML4-ALK FUSION GENE - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene. | 06-20-2013 |
20130153459 | PACKAGE - Provided is a package that exhibits satisfactory moldability as well as moisture adsorption and gas adsorption properties. | 06-20-2013 |
20130150402 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER - A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof and (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular a pharmaceutical composition for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and/or urinary incontinence. | 06-13-2013 |
20130150364 | HETEROCYCLIC COMPOUND | 06-13-2013 |
20130143874 | FUSED RING PYRIDINE COMPOUND - [Problem] To provide a compound useful as a novel agent which is excellent in preventing and/or treating cannabinoid receptor type 2-related diseases, based on agonist action on a cannabinoid receptor type 2 | 06-06-2013 |
20130143860 | GUANIDINE COMPOUND | 06-06-2013 |
20130137739 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND - A solid dispersion comprising a poorly soluble pharmaceutical compound, such as 3-methoxy-1,5-bis(4-methoxyphenyl)-1H-1,2,4-triazole, which has excellent ease of handling and stability is provided. The solid dispersion comprises a polymeric carrier (for example, a polymer selected from a group consisting of polyvinylpyrrolidone and copolyvidone) and further comprising hydroxypropyl methylcellulose as desired. | 05-30-2013 |
20130137111 | DETECTION METHOD OF NOVEL RET FUSION - It was found that a new fusion gene of a portion of the KIF5B gene and a portion of the RET gene, which is present in a portion of cancer patients, is a gene responsible for cancer. Based on this finding, detection methods of a polynucleotide as the gene and a polypeptide encoded by the polynucleotide were established. The detection methods involve detecting a fusion gene of a portion of the KIF5B gene and a portion of the RET gene, or a fusion protein encoded by such a fusion gene. The primer sets and the detection kits comprise sense primers designed from a portion encoding KIF5B and antisense primers designed from a portion encoding RET. | 05-30-2013 |
20130102628 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT - [Problem] A salt or crystal of a compound which is highly stable in a solid state and useful as a bulk material for the preparation of a pharmaceutical product is provided. | 04-25-2013 |
20130102617 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE - Phenylacetamide compounds of the formula | 04-25-2013 |
20130102006 | DETECTION METHOD FOR NOVEL ROS1 FUSIONS - Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1. | 04-25-2013 |
20130096100 | DI(ARYLAMINO)ARYL COMPOUND - The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. | 04-18-2013 |
20130085134 | QUINOXALINE COMPOUND - Quinoxaline compounds of formula (I) have a PDE9-inhibiting action and are useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. | 04-04-2013 |
20130079351 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF - A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia. | 03-28-2013 |
20130059855 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND - Provided are crystals of compound A which have properties suitable for industrial production. | 03-07-2013 |
20130059837 | BENZAZEPINE COMPOUND - Provided is a compound which is useful as an agent for treating or preventing 5-HT | 03-07-2013 |
20130053369 | TETRAHYDROBENZOTHIOPHENE COMPOUND - The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia.
| 02-28-2013 |
20130053363 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | 02-28-2013 |
20130029973 | TETRAHYDROBENZOTHIOPHENE COMPOUND - A compound has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating hyperphosphatemia, preventing hyperphosphatemia, or both. The compound is a tetrahydrobenzothiophene compound. A pharmaceutical composition for treating hyperphosphatemia includes the compound or salt thereof. A method of treating hyperphosphatemia includes administering to a subject an effective amount of the compound or salt thereof. | 01-31-2013 |
20130023535 | METHOD OF PREVENTING AND/OR TREATING DIABETIC NEUROPATHY - The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying). Further, the invention is particularly useful for providing an agent for improving pathophysiology of diabetic neuropathy. | 01-24-2013 |
20130012496 | BENZAZEPINE COMPOUND - Provided is a compound which is useful as an agent for treating or preventing 5-HT | 01-10-2013 |
20120283260 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA - The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists. | 11-08-2012 |
20120277208 | BENZAMIDE COMPOUND - [Problem]A compound which is useful as a GK activator is provided. | 11-01-2012 |
20120239139 | MEDICAL IMPLANTS CONTAINING FK506 (TACROLIMUS) METHODS OF MAKING AND METHODS OF USE THEREOF - Implants and methods of making same are provided for treatment or prophylaxis of coronary or peripheral vascular constrictions or vascular occlusions, and particularly, stenoses or restenoses, that comprise FK506 in chemically covalently bound, non-covalently bound or physically immobilized form. | 09-20-2012 |
20120225830 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 09-06-2012 |
20120225829 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 09-06-2012 |
20120184521 | SUBSTITUTED AMIDE COMPOUND - A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: | 07-19-2012 |
20120184520 | GLYCINE COMPOUND | 07-19-2012 |
20120178735 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF - Provided is a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action. The 2H-chromene compound or derivative is particularly useful for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells. | 07-12-2012 |
20120165309 | HETERO RING DERIVATIVE | 06-28-2012 |
20120136025 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R | 05-31-2012 |
20120088838 | METHODS FOR MAINTAINING EFFECTIVE PLASMA CONCENTRATIONS OF A PHARMACEUTICAL - The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (C | 04-12-2012 |
20120088772 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER - The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of inattention, impulsivity, and hyperactivity in attention deficit/hyperactivity disorder. | 04-12-2012 |
20120070465 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed. | 03-22-2012 |
20120059038 | POLYKETIDE COMPOUND | 03-08-2012 |
20120046292 | DIACYLETHYLENEDIAMINE COMPOUND | 02-23-2012 |
20120046285 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA - The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists. | 02-23-2012 |
20120034250 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | 02-09-2012 |
20120022271 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | 01-26-2012 |
20110319385 | QUINOXALINE COMPOUND | 12-29-2011 |
20110303570 | PACKAGE OF SOLID PHARMACEUTICAL PREPARATION - Provided is a package of a solid pharmaceutical preparation capable of preventing an unpleasant odor and coloring due to hydrolysis progressing during storage of a solid pharmaceutical preparation containing 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.
| 12-15-2011 |
20110294749 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE - A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. | 12-01-2011 |
20110288118 | PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN - Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer. | 11-24-2011 |
20110281919 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER - An object of the present invention is to provide an agent for treating or preventing digestive ulcer that is effective even to ulcer of small intestine and others, for which gastric acid secretion inhibitors such as proton pump inhibitors are ineffective, and is superior to allopurinol in the efficaciousness and the safety. | 11-17-2011 |
20110281906 | SUSTAINED RELEASE FORMULATION FOR TACROLIMUS - A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed. | 11-17-2011 |
20110269744 | Benzazepine Compound - [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT | 11-03-2011 |
20110236436 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed. | 09-29-2011 |
20110236318 | ANIMAL MODEL OF AN EJACULATION-LIKE REFLEX - An animal model of an ejaculation-like reflex, wherein the ejaculation-like reflex is induced by continuous infusion of saline through a catheter extending into the proximal urethra of a non-human male animal, and wherein the urethra of the animal is occluded by extending and bending the penis at the base; and a method of screening a test substance for effectiveness in prevention or treatment of male ejaculatory dysfunction using the animal model. | 09-29-2011 |
20110230545 | EML4-ALK FUSION GENE - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene. | 09-22-2011 |
20110230530 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT - (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive bladder model rat”. Owing to these effects, the above compound is useful as a remedy for overactive bladder. | 09-22-2011 |
20110230467 | 4,6-DIAMINONICOTINAMIDE COMPOUND - [Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. | 09-22-2011 |
20110230463 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF - [Object] Provided is a compound which has an excellent S1P | 09-22-2011 |
20110207729 | BICYCLIC ACYLGUANIDINE DERIVATIVE - An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT | 08-25-2011 |
20110207655 | CYCLIC DEPSIPEPTIDE COMPOUND AND USE THEREOF - [Problem]A compound useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD) or asthma, and a pharmaceutical composition containing the compound as an active ingredient are provided. | 08-25-2011 |
20110201659 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN - The present invention relates to a pharmaceutical composition and method for preventing or treating a zoster-associated pain. The inventors found that an N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide compound useful as a varicella-zoster virus (VZV) unexpectedly has the effect to prevent an irreversible nerve degeneration accompanied by herpes virus infection, and therefore is also useful as an agent for preventing or treating zoster-associated pain, and thus accomplished the present invention. | 08-18-2011 |
20110201616 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF - [Object] A compound which is useful as an EP1 receptor antagonist is provided. | 08-18-2011 |
20110166348 | NOVEL SALT OF MORPHOLINE DERIVATIVE - Provided are an acid addition salt of (+)-2-[(inden-7-yloxy)methyl]morpholine (compound A) and a novel crystal thereof, which are for use as a medicament or a drug substance, and which has high storage stability, particularly high stability against humidity and light. An acid addition salt of the compound A with an acid selected from benzenesulfonic acid and hydrobromic acid is a compound which is isolated in the form of a crystal, is a solid at room temperature, exhibits no hygroscopicity at such a level that causes a problem for use as a medicament or a drug substance, has stability against humidity and light, and is therefore extremely useful as a medicament or a drug substance. | 07-07-2011 |
20110166161 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS - This invention relates to novel heterocyclic carboxamide derivatives and salts thereof. More particularly, it relates to novel heterocyclic carboxamide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease. | 07-07-2011 |
20110160295 | ANTITUMOR AGENT - An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided. | 06-30-2011 |
20110158930 | METHOD FOR TREATMENT OF IRRITABLE BOWEL SYNDROME - A method for treatment of a patient suffering from irritable bowel syndrome with diarrhea or mixed irritable bowel syndrome, which comprises administering to the patient a therapeutically effective amount of ramosetron or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of polycarbophil or a pharmaceutically acceptable salt thereof. | 06-30-2011 |
20110152268 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATING NOCICEPTIVE PAIN - The present invention relates to a pharmaceutical composition for treating nociceptive pain, containing a morpholine derivative or a pharmaceutically acceptable salt thereof, as an active ingredient. The present invention is useful in providing an excellent pharmaceutical composition for treating nociceptive pain. In addition, the present invention is particularly useful in providing a pharmaceutical composition for treating pain accompanying a disease selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, spondylosis deformans, gouty arthritis, juvenile arthritis, scapulohumeral periarthritis, and cervical syndrome, lumbago, lumbago accompanying spondylosis deformans, menalgia, pain and tumentia after inflammation, operation or injury, pain after odontectomy, and cancer pain. In addition, the present invention is particularly useful for alleviating pain in a damaged cartilage region, and is particularly useful for osteoarthritis in which NSAIDs are not effective. | 06-23-2011 |
20110144153 | AMIDE COMPOUND - [Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. | 06-16-2011 |
20110142933 | Controlled Release Dosage Form of Tacrolimus - A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration. | 06-16-2011 |
20110128557 | TABLET PRINTING APPARATUS AND TABLET PRODUCTION METHOD, AND TABLET - There is provided a tablet printing apparatus that can perform printing at a high speed on tablets arbitrarily supplied in volume at irregular intervals and has a high printing quality. A tablet printing apparatus | 06-02-2011 |
20110105460 | TRIAZOLE DERIVATIVE OR SALT THEREOF - [Problem] A compound, which can be used for preventing or treating diseases, in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, in particular, diabetes, insulin resistance, dementia, schizophrenia and depression, is provided. | 05-05-2011 |
20110105420 | AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION THEREOF - [Object] Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an α-amylase inhibitory activity, particularly a pharmaceutical composition for the treatment of diabetes. | 05-05-2011 |
20110065746 | COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID FORMULATION - A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor. | 03-17-2011 |
20110059077 | HUMANIZED ANTI-HUMAN ALPHA 9-INTEGRIN ANTIBODY - The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody. | 03-10-2011 |
20110053912 | PYRIMIDINE COMPOUND - A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like. | 03-03-2011 |
20110039822 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS - The present invention provides a compound having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. | 02-17-2011 |
20110034504 | AGENT FOR PREVENTING AND/OR TREATING VASCULAR DISEASES - [Object] To provide an excellent pharmaceutical composition for preventing and/or treating vascular diseases. | 02-10-2011 |
20110028463 | AMIDE COMPOUNDS - [Problems] To provide a compound that is useful as an agent for treating chronic renal insufficiency or an agent for treating diabetic nephropathy.
| 02-03-2011 |
20110009379 | INDOLINONE COMPOUND - [Problems] A compound, which is useful as an active ingredient for a pharmaceutical composition, for example a pharmaceutical composition for treating constipation-type irritable bowel syndrome, atonic constipation and/or functional gastrointestinal disorder, is provided. | 01-13-2011 |
20110003757 | PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE - The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and/or nonalcoholic steatohepatitis in another embodiment. | 01-06-2011 |
20100286171 | PHENYLACETAMIDE DERIVATIVE - A phenylacetamide derivative having sulfonyl group and cycloalkyl group on the phenyl group and having heteroaryl group on the nitrogen atom in the amide has an excellent GK activation action, thereby completing the present invention. The compound of the present invention is useful as an agent for treating diabetes, in particular, type II diabetes, since it has an excellent GK activation action. | 11-11-2010 |
20100273825 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN AMORPHOUS FORM - The present invention relates to the provision of a stable solid pharmaceutical composition containing an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof and capable of inhibiting decomposition accompanied by long-term storage, to provide the medical field with a formulation of solifenacin or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a solid pharmaceutical composition, comprising an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof, and one stabilizer for amorphous solifenacin or two or more stabilizers for amorphous solifenacin, selected from the group consisting of citric acid or a pharmaceutically acceptable salt (excluding a calcium salt) thereof, sodium pyrosulfite, and a pharmaceutically acceptable salt of ethylenediaminetetraacetic acid. | 10-28-2010 |
20100267695 | FUSED INDANE COMPOUND - [Problems] To provide a compound which is useful as an NMDA receptor antagonist. | 10-21-2010 |
20100249088 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF - [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. | 09-30-2010 |
20100240697 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER - [Problems] To provide a pharmaceutical composition which is useful as a therapeutic agent for overactive bladder. | 09-23-2010 |
20100240673 | EML4-ALK Fusion Gene - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene. | 09-23-2010 |
20100233260 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance. | 09-16-2010 |
20100227866 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF - [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). | 09-09-2010 |
20100222361 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF - A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia. | 09-02-2010 |
20100222329 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF - A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia. | 09-02-2010 |
20100221223 | IMMUNE RESPONSE INDUCTION METHOD - The present invention proposes a method of inducing both vaccine antigen-specific antibody in blood and vaccine antigen-specific antibody secreted at the mucosal surface using vaccine antigen and adjuvant of said vaccine antigen. | 09-02-2010 |
20100216803 | ORNITHINE DERIVATIVE - Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. | 08-26-2010 |
20100216798 | FUSED HETEROCYCLES AS LCK INHIBITORS - There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. | 08-26-2010 |
20100216778 | PAIN REMEDY CONTAINING ROCK INHIBITOR - Since a ROCK inhibitor exerts a potent analgesic effect by a single dose after the onset of a cartilage-related disease such as osteoarthritis, and can regenerate or suppress destruction of cartilage tissue and alleviate pain associated with cartilage diseases by multiple doses, administration of an therapeutically effective amount of the ROCK inhibitor to a patient with cartilage-related disease such as osteoarthritis or rheumatoid arthritis can treat the patient with cartilage-related disease and the ROCK inhibitor is thus useful. | 08-26-2010 |
20100183713 | GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM - The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The system provides site-specific release of the drug to both the small intestine and the colon in the form of multiple controlled doses for long-lasting efficacy, thereby reducing the drug dosing frequency. | 07-22-2010 |
20100173946 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF - Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases. | 07-08-2010 |
20100168159 | HETERO COMPOUND | 07-01-2010 |
20100168154 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND - Provided is a compound useful as an N-type Ca | 07-01-2010 |
20100151034 | GRANULAR PHARMACEUTICAL COMPOSITION OF ATORVASTATIN FOR ORAL ADMINISTRATION - A granular pharmaceutical composition for oral administration, comprising (1) atorvastatin or a pharmaceutically acceptable salt thereof, (2) a surfactant selected from the group consisting of sodium laurylsulfate and polyoxyethylene hydrogenated castor oil, and (3) a water-soluble polymer, is disclosed. | 06-17-2010 |
20100144807 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed. | 06-10-2010 |
20100144792 | NEURITE FORMATION PROMOTER - The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction. | 06-10-2010 |
20100144711 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - A pharmaceutical composition for oral administration, comprising 3-hydroxy-N | 06-10-2010 |
20100144677 | METHOD FOR SCREENING AGENTS FOR THE TREATMENT OF DIABETES - A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. | 06-10-2010 |
20100136110 | GRANULAR PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - A granular pharmaceutical composition for oral administration, wherein a drug-containing particle is coated with a coating comprising a methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer and a water-soluble polymer is disclosed. | 06-03-2010 |
20100129345 | SCREENING METHOD FOR PROKINETIC AGENT - The present invention provides a screening tool and screening method for obtaining a substance useful as a prophylactic and/or therapeutic drug for diseases associated 5 with 5-HT production/secretion abnormalities, including digestive organ diseases, and a prophylactic and/or therapeutic drug for diseases associated with 5-HT production/secretion abnormalities, including digestive organ diseases. Examples of digestive organ diseases in the present invention include constipation type irritable bowel syndrome, functional dyspepsia, constipation, diarrhea type irritable bowel syndrome, diarrhea and vomiting. | 05-27-2010 |
20100113451 | NOVEL PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DIABETIC NEUROPATHY - The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying). Further, the invention is particularly useful for providing an agent for improving pathophysiology of diabetic neuropathy. | 05-06-2010 |
20100113391 | BICYCLIC HETEROCYCLIC COMPOUND | 05-06-2010 |
20100105661 | CONDENSED PYRIDINE COMPOUND - The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. | 04-29-2010 |
20100105658 | AZA-BRIDGED-RING COMPOUND - [Problems] Provided is a compound which has an antagonistic action on a muscarinic M | 04-29-2010 |
20100099658 | DI(ARYLAMINO)ARYL COMPOUND - The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. | 04-22-2010 |
20100094025 | METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF - The present invention provides a method for producing a C-glycoside derivative, which can produce the C-glycoside derivative at a high yield and at a low cost, which conforms to environmental protection, and which is applicable industrially. The C-glycoside derivative is useful for treating and preventing diabetes such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes) and the like and various diabetes-related diseases including insulin-resistant diseases and obesity. | 04-15-2010 |
20100087439 | NOVEL PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN - The present invention relates to an agent for preventing and/or treating neuropathic pain comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating neuropathic pain, and particularly useful for providing an agent for preventing and/or treating allodynia, hyperalgesia, hyperesthesia, spontaneous pain, cancer pain, trigeminal neuralgia, phantom limb pain, postherpetic neuralgia, fibromyalgia, low back/leg pain, thalamic pain, entrapment (compressive) peripheral neuropathy, atypical facial pain, pain accompanying spinal cord injury, pain accompanying multiple sclerosis, pain accompanying chemotherapy-induced neuropathy, cancer pain on which an analgesic effect of a narcotic analgesic such as morphine is insufficient, pain accompanying diabetic neuropathy, and the like. | 04-08-2010 |
20100069388 | N-HYDROXYACRYLAMIDE COMPOUNDS - A compound having the following formula (I): wherein —R | 03-18-2010 |
20100063098 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS - A compound represented by the formula (I): wherein R | 03-11-2010 |
20100062063 | LIGHT-STABLE SOLID PHARMACEUTICAL COMPOSITION OF RAMOSETRON - Provided is a preparation of ramosetron which is stable under irradiation with light. The solid pharmaceutical composition of the present invention can provide a stable preparation by blending a compound absorbing light having a specific wavelength with ramosetron which is unstable, usually under irradiation with light, or a pharmaceutically acceptable salt thereof. Particularly, this technique is useful because it is adaptable to a preparation containing ramosetron or a pharmaceutically acceptable salt thereof at a low content or an orally disintegrating tablet containing ramosetron or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by blending a compound having characteristics of absorbing light having a specific wavelength. | 03-11-2010 |
20100041668 | Compositions and methods for treating thrombocytopenia - The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that agonizes the human TPO receptor by binding to a binding site of the human TPO receptor distinct from the rhTPO binding site. | 02-18-2010 |
20100030530 | METHOD OF SEARCHING FOR LIGAND - Disclosed is a method of searching for a ligand capable of binding to a target biomacromolecule, comprising the step of:
| 02-04-2010 |
20100029687 | PIPERIDINE DERIVATIVE OR SALT THEREOF - [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. | 02-04-2010 |
20100009991 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS - The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like. | 01-14-2010 |
20090317455 | REVERSE TARGETING LIPID VESICLE - The present invention provides an immunomodulating agent and a therapeutic agent for a immune disease, which comprise a lipid vesicle encapsulating a drug capable of suppressing or damaging an immunocyte that expresses or binds to an antibody, the lipid vesicle having an antigen for the antibody bound to the outer surface thereof. Hence, there is provided means for effectively treating an immune disease such as an allergic diseases or an autoimmune disease. | 12-24-2009 |
20090312328 | SULFONAMIDE COMPOUND OR SALT THEREOF - [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom. | 12-17-2009 |
20090281142 | THIAZOLE DERIVATIVE - [Problem] To provide a compound which is useful as a GK activator. | 11-12-2009 |
20090270463 | AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing a solid dispersion comprising an amide derivative or a salt thereof and a water-soluble polymer, wherein the pharmaceutical composition is not prepared by a melting method. The pharmaceutical composition contains the solid dispersion having an improved oral absorption, properties suitable for formulation, and an excellent stability. | 10-29-2009 |
20090270376 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS - The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia). | 10-29-2009 |
20090270365 | BENZAMIDE DERIVATIVE OR SALT THEREOF - There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. | 10-29-2009 |
20090264617 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 10-22-2009 |
20090264399 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS - The invention relates to compound of the formula (I) or its salt, wherein —R | 10-22-2009 |
20090264343 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 10-22-2009 |
20090263390 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS - The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin -2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents. | 10-22-2009 |
20090239791 | PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC SUBSTANCE WHICH INHIBITS IL-2 PRODUCTION - A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects. | 09-24-2009 |
20090203741 | CRYSTALS OF BENZOXADIAZOLE DERIVATIVE - Object Provided are β-form crystal, γ-form crystal, and α-form crystal of a benzoxadiazole derivative, wherein a uniform crystal having sufficient qualities can be obtained with high reproducibility, and they can be anytime supplied as crystals of drug substance for use in producing pharmaceuticals, are particularly suitable for mass synthesis in industrial production, hardly exhibit hygroscopicity and have particularly excellent photo-resistance. | 08-13-2009 |
20090197834 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - [Problem] To provide a compound having excellent platelet aggregation inhibitory activity. | 08-06-2009 |
20090186916 | AMINOINDANE DERIVATIVE OR SALT THEREOF - Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. | 07-23-2009 |
20090156785 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 06-18-2009 |
20090149436 | CASPASE INHIBITOR - The present invention provides a caspase inhibitor containing a cobalt porphyrin complex compound or cobalt choline complex compound as an active ingredient. The caspase inhibitor of the present invention can strongly and specifically inhibit the caspase activity. In addition, the caspase inhibitor/cobalt porphyrin complex compound or cobalt choline complex compound of the present invention is useful as a pharmaceutical agent for the prophylaxis or treatment of various diseases relating to apoptosis. | 06-11-2009 |
20090143316 | COCRYSTAL OF C-GLYCOSIDE DERIVATIVE AND L-PROLINE - A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals. | 06-04-2009 |
20090137498 | SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF - There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4′-bromo-2′-[(5-chloro-2-pyridyl)carbamoyl]-6′-β-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2′-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4′-bromo-6′-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof. | 05-28-2009 |
20090131666 | ACYLAMINOPIPERIDINE COMPOUND - [Problem] To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like.
| 05-21-2009 |
20090131484 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE - [Problem] To provide a preventive or a remedy for various diarrheas caused by inflammatory colitis, irritable bowel syndrome and other factors. | 05-21-2009 |
20090131469 | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN - There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic bladder caused by neurodegenerative diseases such as cerebrovascular disease or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital malformation of the nerve system, peripheral neuropathy, and various spine lesions, that is, spinal cord compression and injury due to fracture, cervical and lumbar spondylosis, spondylosis deformans, spondylolisthesis, spinal stenosis, vertebral disk hernia and the like. | 05-21-2009 |
20090124617 | QUINOLONE DERIVATIVE OR SALT THEREOF - A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor. | 05-14-2009 |
20090119786 | Model animal of schizophrenia - A non-human transgenic animal exhibiting schizophrenic symptoms in which a polynucleotide encoding SREB2 whose overexpression in the brain causes schizophrenia and a polynucleotide comprising a promoter are introduced; and a method of screening for a therapeutic agent for schizophrenia, comprising the steps of administrating a test substance to the animal, determining a schizophrenia-related disorder in the animal, and selecting the substance exhibiting a therapeutic effect on schizophrenia are disclosed. According to the present invention, a model animal of schizophrenia in which the genetic background that causes schizophrenia is reflected, and an in vivo screening method for a therapeutic agent for schizophrenia can be provided. | 05-07-2009 |
20090105231 | AMIDE DERIVATIVES AS ROCK INHIBITORS - This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease. | 04-23-2009 |
20090105130 | DEPSIPEPTIDE-CONTAINING INJECTION SOLUTION - [Problems] An injection preparation containing a depsipeptide having a disulfide bond in its molecule, which can be easily prepared, and which is stable, is provided. | 04-23-2009 |
20090099193 | EML4-ALK FUSION GENE - The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer. | 04-16-2009 |
20090093415 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - [Problem]To provide a therapeutic agent for irritable bowel syndrome (IBS), which is excellent in efficacy and safety. | 04-09-2009 |
20090082367 | TRIAZOLE DERIVATIVE OR A SALT THEREOF - [Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. | 03-26-2009 |
20090076070 | HETERO COMPOUND - [Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P | 03-19-2009 |
20090074858 | SUSTAINED-RELEASE FORMULATION - A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient. | 03-19-2009 |
20090069252 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF - The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na | 03-12-2009 |
20090062363 | AMIDE DERIVATIVE OR SALT THEREOF - [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT | 03-05-2009 |
20090054464 | HDAC INHIBITOR - Compounds having the formula (I): | 02-26-2009 |
20090054352 | BENZENE DERIVATIVE OR SALT THEREOF - Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. | 02-26-2009 |
20090053212 | HUMANIZED ANTI-HUMAN OSTEOPONTIN ANTIBODY - The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies. | 02-26-2009 |